Katherine B Howell1,2,3, Stefanie Eggers3, Kim Dalziel3,4, Jessica Riseley3, Simone Mandelstam2,3,5,6,7, Candace T Myers8, Jacinta M McMahon9, Amy Schneider9, Gemma L Carvill10, Heather C Mefford8, Ingrid E Scheffer1,2,7,9, A Simon Harvey1,2,3. 1. Department of Neurology, Royal Children's Hospital, Melbourne, Victoria, Australia. 2. Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia. 3. Murdoch Children's Research Institute, Melbourne, Victoria, Australia. 4. Melbourne School of Global and Population Health, University of Melbourne, Melbourne, Victoria, Australia. 5. Department of Medical Imaging, Royal Children's Hospital, Melbourne, Victoria, Australia. 6. Department of Radiology, University of Melbourne, Melbourne, Victoria, Australia. 7. Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, Australia. 8. Division of Genetic Medicine, Department of Pediatrics, University of Washington, Seattle, WA, USA. 9. Department of Medicine, Epilepsy Research Centre, Austin Health, University of Melbourne, Melbourne, Victoria, Australia. 10. Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Abstract
OBJECTIVE: The severe epilepsies of infancy (SEI) are a devastating group of disorders that pose a major care and economic burden on society; early diagnosis is critical for optimal management. This study sought to determine the incidence and etiologies of SEI, and model the yield and cost-effectiveness of early genetic testing. METHODS: A population-based study was undertaken of the incidence, etiologies, and cost-effectiveness of a whole exome sequencing-based gene panel (targeted WES) in infants with SEI born during 2011-2013, identified through electroencephalography (EEG) and neonatal databases. SEI was defined as seizure onset before age 18 months, frequent seizures, epileptiform EEG, and failure of ≥2 antiepileptic drugs. Medical records, investigations, MRIs, and EEGs were analyzed, and genetic testing was performed if no etiology was identified. Economic modeling was performed to determine yield and cost-effectiveness of investigation of infants with unknown etiology at epilepsy onset, incorporating targeted WES at different stages of the diagnostic pathway. RESULTS: Of 114 infants with SEI (incidence = 54/100 000 live births/y), the etiology was determined in 76 (67%): acquired brain injuries (n = 14), focal cortical dysplasias (n = 14), other brain malformations (n = 17), channelopathies (n = 11), chromosomal (n = 9), metabolic (n = 6), and other genetic (n = 5) disorders. Modeling showed that incorporating targeted WES increased diagnostic yield compared to investigation without targeted WES (48/86 vs 39/86). Early targeted WES had lower total cost ($677 081 U.S. dollars [USD] vs $738 136 USD) than late targeted WES. A pathway with early targeted WES and limited metabolic testing yielded 7 additional diagnoses compared to investigation without targeted WES (46/86 vs 39/86), with lower total cost ($455 597 USD vs $661 103 USD), lower cost per diagnosis ($9904 USD vs $16 951 USD), and a dominant cost-effectiveness ratio. SIGNIFICANCE: Severe epilepsies occur in 1 in 2000 infants, with the etiology identified in two-thirds, most commonly malformative. Early use of targeted WES yields more diagnoses at lower cost. Early genetic diagnosis will enable timely administration of precision medicines, once developed, with the potential to improve long-term outcome. Wiley Periodicals, Inc.
OBJECTIVE: The severe epilepsies of infancy (SEI) are a devastating group of disorders that pose a major care and economic burden on society; early diagnosis is critical for optimal management. This study sought to determine the incidence and etiologies of SEI, and model the yield and cost-effectiveness of early genetic testing. METHODS: A population-based study was undertaken of the incidence, etiologies, and cost-effectiveness of a whole exome sequencing-based gene panel (targeted WES) in infants with SEI born during 2011-2013, identified through electroencephalography (EEG) and neonatal databases. SEI was defined as seizure onset before age 18 months, frequent seizures, epileptiform EEG, and failure of ≥2 antiepileptic drugs. Medical records, investigations, MRIs, and EEGs were analyzed, and genetic testing was performed if no etiology was identified. Economic modeling was performed to determine yield and cost-effectiveness of investigation of infants with unknown etiology at epilepsy onset, incorporating targeted WES at different stages of the diagnostic pathway. RESULTS: Of 114 infants with SEI (incidence = 54/100 000 live births/y), the etiology was determined in 76 (67%): acquired brain injuries (n = 14), focal cortical dysplasias (n = 14), other brain malformations (n = 17), channelopathies (n = 11), chromosomal (n = 9), metabolic (n = 6), and other genetic (n = 5) disorders. Modeling showed that incorporating targeted WES increased diagnostic yield compared to investigation without targeted WES (48/86 vs 39/86). Early targeted WES had lower total cost ($677 081 U.S. dollars [USD] vs $738 136 USD) than late targeted WES. A pathway with early targeted WES and limited metabolic testing yielded 7 additional diagnoses compared to investigation without targeted WES (46/86 vs 39/86), with lower total cost ($455 597 USD vs $661 103 USD), lower cost per diagnosis ($9904 USD vs $16 951 USD), and a dominant cost-effectiveness ratio. SIGNIFICANCE: Severe epilepsies occur in 1 in 2000 infants, with the etiology identified in two-thirds, most commonly malformative. Early use of targeted WES yields more diagnoses at lower cost. Early genetic diagnosis will enable timely administration of precision medicines, once developed, with the potential to improve long-term outcome. Wiley Periodicals, Inc.
Authors: Lily C Wong-Kisiel; Jeffrey W Britton; Robert J Witte; Kristen M Kelly-Williams; Amy L Kotsenas; Karl N Krecke; Robert E Watson; Alice Patton; Dennis P Hanson; Jay Mandrekar Journal: Pediatr Neurol Date: 2016-05-05 Impact factor: 3.372
Authors: Nicholas M Allen; Judith Conroy; Amre Shahwan; Sean Ennis; Bryan Lynch; Sally A Lynch; Mary D King Journal: Eur J Paediatr Neurol Date: 2015-04-10 Impact factor: 3.140
Authors: Johannes R Lemke; Erik Riesch; Tim Scheurenbrand; Max Schubach; Christian Wilhelm; Isabelle Steiner; Jörg Hansen; Carolina Courage; Sabina Gallati; Sarah Bürki; Susi Strozzi; Barbara Goeggel Simonetti; Sebastian Grunt; Maja Steinlin; Michael Alber; Markus Wolff; Thomas Klopstock; Eva C Prott; Rüdiger Lorenz; Christiane Spaich; Sabine Rona; Maya Lakshminarasimhan; Judith Kröll; Thomas Dorn; Günter Krämer; Matthis Synofzik; Felicitas Becker; Yvonne G Weber; Holger Lerche; Detlef Böhm; Saskia Biskup Journal: Epilepsia Date: 2012-05-21 Impact factor: 5.864
Authors: Jo M Wilmshurst; William D Gaillard; Kollencheri Puthenveettil Vinayan; Tammy N Tsuchida; Perrine Plouin; Patrick Van Bogaert; Jaime Carrizosa; Maurizio Elia; Dana Craiu; Nebojsa J Jovic; Doug Nordli; Deborah Hirtz; Virginia Wong; Tracy Glauser; Eli M Mizrahi; J Helen Cross Journal: Epilepsia Date: 2015-06-30 Impact factor: 5.864
Authors: Brian J O'Roak; Laura Vives; Wenqing Fu; Jarrett D Egertson; Ian B Stanaway; Ian G Phelps; Gemma Carvill; Akash Kumar; Choli Lee; Katy Ankenman; Jeff Munson; Joseph B Hiatt; Emily H Turner; Roie Levy; Diana R O'Day; Niklas Krumm; Bradley P Coe; Beth K Martin; Elhanan Borenstein; Deborah A Nickerson; Heather C Mefford; Dan Doherty; Joshua M Akey; Raphael Bernier; Evan E Eichler; Jay Shendure Journal: Science Date: 2012-11-15 Impact factor: 47.728
Authors: Jay G Berry; Annapurna Poduri; Joshua L Bonkowsky; Jing Zhou; Dionne A Graham; Chelsea Welch; Heather Putney; Rajendu Srivastava Journal: PLoS Med Date: 2012-01-17 Impact factor: 11.069
Authors: Glen R Monroe; Gerardus W Frederix; Sanne M C Savelberg; Tamar I de Vries; Karen J Duran; Jasper J van der Smagt; Paulien A Terhal; Peter M van Hasselt; Hester Y Kroes; Nanda M Verhoeven-Duif; Isaäc J Nijman; Ellen C Carbo; Koen L van Gassen; Nine V Knoers; Anke M Hövels; Mieke M van Haelst; Gepke Visser; Gijs van Haaften Journal: Genet Med Date: 2016-02-04 Impact factor: 8.822
Authors: Andrew S Allen; Samuel F Berkovic; Patrick Cossette; Norman Delanty; Dennis Dlugos; Evan E Eichler; Michael P Epstein; Tracy Glauser; David B Goldstein; Yujun Han; Erin L Heinzen; Yuki Hitomi; Katherine B Howell; Michael R Johnson; Ruben Kuzniecky; Daniel H Lowenstein; Yi-Fan Lu; Maura R Z Madou; Anthony G Marson; Heather C Mefford; Sahar Esmaeeli Nieh; Terence J O'Brien; Ruth Ottman; Slavé Petrovski; Annapurna Poduri; Elizabeth K Ruzzo; Ingrid E Scheffer; Elliott H Sherr; Christopher J Yuskaitis; Bassel Abou-Khalil; Brian K Alldredge; Jocelyn F Bautista; Samuel F Berkovic; Alex Boro; Gregory D Cascino; Damian Consalvo; Patricia Crumrine; Orrin Devinsky; Dennis Dlugos; Michael P Epstein; Miguel Fiol; Nathan B Fountain; Jacqueline French; Daniel Friedman; Eric B Geller; Tracy Glauser; Simon Glynn; Sheryl R Haut; Jean Hayward; Sandra L Helmers; Sucheta Joshi; Andres Kanner; Heidi E Kirsch; Robert C Knowlton; Eric H Kossoff; Rachel Kuperman; Ruben Kuzniecky; Daniel H Lowenstein; Shannon M McGuire; Paul V Motika; Edward J Novotny; Ruth Ottman; Juliann M Paolicchi; Jack M Parent; Kristen Park; Annapurna Poduri; Ingrid E Scheffer; Renée A Shellhaas; Elliott H Sherr; Jerry J Shih; Rani Singh; Joseph Sirven; Michael C Smith; Joseph Sullivan; Liu Lin Thio; Anu Venkat; Eileen P G Vining; Gretchen K Von Allmen; Judith L Weisenberg; Peter Widdess-Walsh; Melodie R Winawer Journal: Nature Date: 2013-08-11 Impact factor: 49.962
Authors: Gemma L Carvill; Krysta L Engel; Aishwarya Ramamurthy; J Nicholas Cochran; Jolien Roovers; Hannah Stamberger; Nicholas Lim; Amy L Schneider; Georgie Hollingsworth; Dylan H Holder; Brigid M Regan; James Lawlor; Lieven Lagae; Berten Ceulemans; E Martina Bebin; John Nguyen; Gregory S Barsh; Sarah Weckhuysen; Miriam Meisler; Samuel F Berkovic; Peter De Jonghe; Ingrid E Scheffer; Richard M Myers; Gregory M Cooper; Heather C Mefford Journal: Am J Hum Genet Date: 2018-12-06 Impact factor: 11.025
Authors: Tim A Benke; Kristen Park; Ilona Krey; Chad R Camp; Rui Song; Amy J Ramsey; Hongjie Yuan; Stephen F Traynelis; Johannes Lemke Journal: Neuropharmacology Date: 2021-09-22 Impact factor: 5.250